What was Sun Pharma’s net profit in Q3 FY25–26?
- Answer Field
-
Sun Pharmaceutical Industries Limited reported a consolidated net profit of ₹3,368.81 crore in Q3 FY25–26.
Sun Pharmaceutical Industries Limited reported consolidated revenue from operations of ₹15,520.54 crore in Q3 FY25–26. Net profit for the quarter stood at ₹3,368.81 crore, reflecting profitability compared with the same quarter last year. An interim dividend of ₹11 per equity share for the financial year 2025-26 is declared.
Sun Pharmaceutical Industries Limited announced its unaudited consolidated financial results for the quarter and nine months ended 31 December 2025 (Q3 FY25–26). The results were approved by the Board of Directors at its meeting held on 31 January 2026 and subsequently disclosed to the stock exchanges.
For the quarter, the company reported revenue from operations of ₹15,520.54 crore, compared with ₹13,675.46 crore in Q3 FY24–25. Net profit of the company stood at ₹3,368.81 crore, as per the exchange filing. An interim dividend of ₹11 per equity share for the financial year 2025-26 is declared
Sun Pharmaceutical Industries Limited declared its Q3 FY25–26 financial results on 31 January 2026, following approval by the Board of Directors. Along with the financial results, the company also announced an interim dividend for the financial year.
The Company declared an interim dividend of ₹11 for each equity share for the financial year 2025-26. On 20 January 2026, the company announced that the record date for entitlement of the interim dividend for the financial year 2025-26 is 05 February 2026. The interim dividend shall be paid on or before 16 February 2026.
All figures in ₹ crore | Unaudited
Particulars | Q3 FY25–26 | Q2 FY25–26 | Q3 FY24–25 | QoQ % | YoY % |
Revenue from Operations | 15,520.54 | 14,478.31 | 13,675.46 | 7.2% | 13.5% |
Other Income | 578.84 | 469.92 | 465.62 | 23.2% | 26.8% |
Total Income | 16,099.38 | 14,948.23 | 14,141.08 | 7.7% | 13.8% |
Total Expenses | 11,382.74 | 10,780.62 | 10,348.51 | 5.6% | 10.0% |
Profit Before Tax | 4,227.16 | 4,167.61 | 3,476.40 | 1.4% | 21.6% |
Net Profit | 3,368.81 | 3,117.95 | 2,903.38 | 8.0% | 16.0% |
EPS – Basic (₹) | 14.00 | 13.00 | 12.10 | 7.7% | 15.7% |
EPS – Diluted (₹) | 14.00 | 13.00 | 12.10 | 7.7% | 15.7% |
All figures in ₹ crore | Unaudited
Particulars | Q3 FY25–26 | Q2 FY25–26 | QoQ Change (%) |
Revenue from Operations | 15,520.54 | 14,478.31 | 7.2% |
Profit Before Tax | 4,227.16 | 4,167.61 | 1.4% |
Net Profit | 3,368.81 | 3,117.95 | |
EPS – Basic (₹) | 14.00 | 13.00 | 7.7% |
Sequentially, revenue and net profit improved during the quarter.
As per the exchange filing, Sun Pharmaceutical Industries Limited operates under a single reportable segment, namely Pharmaceuticals. Accordingly, segment-wise financial information is presented on a consolidated basis.
Sun Pharmaceutical Industries Limited released its quarterly results on January 31, 2026, which was a Saturday when markets were closed. As of 3:30 PM IST on 30 January 2026, Sun Pharmaceutical Industries Limited shares were trading at ₹1,595.00, up by ₹5.70, or 0.36%, compared with the previous close, according to NSE data.
Sun Pharma’s Q3 FY25–26 results indicate a positive year-on-year performance, with higher revenue and net profit compared with the same quarter last year. The company continued to report steady operating execution during the period.
For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.
No result found
Sun Pharmaceutical Industries Limited reported a consolidated net profit of ₹3,368.81 crore in Q3 FY25–26.
The company recorded consolidated revenue from operations of ₹15,520.54 crore during the quarter.
Yes. Sun Pharma announced an interim dividend of ₹11.00 per equity share for FY25–26.
On a year-on-year basis, Sun Pharma reported higher revenue and net profit compared with Q3 FY24–25.
No. Sun Pharma operates under a single reportable segment, Pharmaceuticals, as per the exchange filing.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading